Valuation: Arctic Bioscience

Market Cap 87.34M 9.03M 7.89M 7.29M 6.74M 12.69M 867M 12.92M 86.99M 34.13M 425M 33.92M 33.17M 1.46B P/E 2026 *
-3.64x
P/E 2027 * -
Enterprise Value 153M 15.85M 13.85M 12.81M 11.83M 22.28M 1.52B 22.69M 153M 59.92M 746M 59.55M 58.23M 2.57B EV / Sales 2026 *
2.64x
EV / Sales 2027 * -
Free-Float
47.75%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week-0.31%
1 month-5.54%
3 months+0.31%
6 months-8.73%
Current year-1.22%
1 week 2.8
Extreme 2.8
3.4
1 month 2.6
Extreme 2.6
3.4
Current year 2.6
Extreme 2.6
3.67
1 year 2.6
Extreme 2.6
4.65
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 2010-12-31
Chief Executive Officer 54 2022-02-28
Director of Finance/CFO 47 2022-03-31
Director TitleAgeSince
Chairman 68 2015-11-30
Director/Board Member 55 2014-12-31
Director/Board Member 46 2020-12-31
Date Insider Type Main position Quantity % Market Cap.
23-04-23Buy

Director

943,833 3.8641%
23-04-23Buy

Director

943,833 3.8641%
23-02-22Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%-0.31%-14.51%-68.70% 9.03M
-2.48%-6.72%+44.19%+156.43% 1,028B
-1.52%-5.01%+61.87%+58.79% 611B
-1.30%-3.88%+27.81%+79.97% 432B
-1.12%-3.68%+26.89%+20.58% 323B
-1.73%-3.45%+26.95%+44.09% 277B
-1.95%-13.92%+15.96%+19.76% 257B
-1.45%-2.37%-27.87%-39.87% 217B
-1.44%-3.49%+19.60%+56.20% 192B
-1.04%-4.63%+16.01%+68.47% 161B
Average -1.14%-3.68%+19.69%+39.57% 349.83B
Weighted average by Cap. -0.90%-4.76%+33.11%+76.73%

Financials

2026 *2027 *
Net sales 58M 6M 5.24M 4.84M 4.48M 8.43M 576M 8.58M 57.77M 22.67M 282M 22.52M 22.03M 971M -
Net income -24M -2.48M -2.17M -2M -1.85M -3.49M -238M -3.55M -23.9M -9.38M -117M -9.32M -9.11M -402M -
Net Debt 66M 6.82M 5.96M 5.51M 5.09M 9.59M 655M 9.76M 65.74M 25.79M 321M 25.63M 25.06M 1.11B -
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
26-07-14 NOK 3.240 -0.31% 1,182
26-07-13 NOK 3.250 +1.88% 17,129
26-07-10 NOK 3.190 -1.85% 2,053
26-07-09 NOK 3.250 0.00% 0
26-07-08 NOK 3.250 0.00% 0
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise